Joint Diseases and Related Surgery has published a four-week rat Achilles tendon study comparing BPC-157, synthetic thymosin beta-4 (TB-500), and the two in combination, against repair with no peptide. Thirty-two animals were randomised into four groups after standardised transection and repair, then assessed biomechanically, histopathologically, histochemically and immunohistochemically.
Both peptides were associated with better histopathological scores and more organised extracellular matrix than control. TB-500 also reached a significant biomechanical advantage on maximum load to failure, while BPC-157 moved in the same direction without reaching significance on total scores. The combination gave no additional benefit over either peptide alone, which the authors suggest may reflect convergence on shared downstream pathways. They describe the results as exploratory and preliminary, pending longer studies.
Catalogue note
BPC-157 is RGF-01, TB-500 is RGF-02, and the fixed co-formulation of the two is RGF-03. This is animal work, and we are posting it because a controlled head-to-head is the thing the literature on these two peptides mostly lacks — not because it says anything about use in a person. We publish no dosing information and will not supply any on request.
Source: Biçer O and colleagues, Joint Diseases and Related Surgery, 23 July 2026. PubMed 42542926.